Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)?

Cell Research

Volumn 19, Issue 10, 2009, Pages 1221-1224

  Yu, Kunqian ^a   Luo, Cheng ^a   Qin, Guangrong ^a   Xu, Zhijian ^a   Li, Ning ^a   Liu, Hong ^a   Shen, Xu ^a   Ma, Jianpeng ^b   Wang, Qinghua ^b   Yang, Caiguang ^a   Zhu, Weiliang ^a   Jiang, Hualiang ^a,c  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; ZANAMIVIR;

ARTICLE; BINDING SITE; CHEMISTRY; COMPUTER SIMULATION; GENETICS; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ANTIVIRAL AGENTS; BASE SEQUENCE; BINDING SITES; COMPUTER SIMULATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MOLECULAR SEQUENCE DATA; OSELTAMIVIR; ZANAMIVIR;

INFLUENZA A VIRUS; INFLUENZAVIRUS A;

EID: 70349786394     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2009.111     Document Type: Article

References (15)

1. Alexander DJ. An overview of the epidemiology of avian influenza. Vaccine 2007; 25:5637-5644.
2. Skeik N, Jabr FI. Influenza viruses and the evolution of avian influenza virus H5N1. Int J Infect Dis 2008; 12:233-238.
3. Taubenberger JK, Reid AH, Lourens RM, et al. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437:889-893.
4. Tumpey TM, Maines TR, Hoeven NV, et al. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science 2007; 315:655-659.
5. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443:45-49.
6. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515-4520.
7. Mitrasinovic PM. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). Biophys Chem 2009; 140:35-38.
8. Wade RC. 'Flu' and structure-based drug design. Structure 1997; 5:1139-1145.
9. Rameix-Welti MA, Enouf V, Cuvelier F, et al. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog 2008; 4:e1000103.
10. Mihajlovic ML, Mitrasinovic PM. Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV). Biophys Chem 2008; 136:152-158.
11. Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol 1990; 215:403-410.
12. Collins PJ, Haire LF, Lin PY, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008; 453:1258-1261.
13. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19:1639-1662.
14. Pearlman DA, Case DA, Caldwell JW, et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comp Phys Commun 1995; 91:1-41.
15. Chen LL, Gui CS, Luo X, et al. Cinanserin is an inhibitor of the 3C-Like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol 2005; 79:7095-7103.